Big Name Brands Poised To Lose US Exclusivity In 2025
J&J’s Stelara, Amgen’s Prolia, Novartis’s Entresto and AstraZeneca’s Brilinta are among the drugs that will likely face generic or biosimilar competition for the first time this year.
J&J’s Stelara, Amgen’s Prolia, Novartis’s Entresto and AstraZeneca’s Brilinta are among the drugs that will likely face generic or biosimilar competition for the first time this year.